A lab assistant tests drugs at a pharmaceutical company in Harbin, capital of Heilongjiang province, on March 4, 2020. (Photo/Xinhua)
Chinese researchers have completed clinical studies of favipiravir, which shows promising clinical efficacy in treating the novel coronavirus pneumonia, Zhang Xinmin, head of the China National Center for Biotechnology Development, said on Tuesday.
Experiments have shown that patients treated with favipiravir recovered more quickly and their lung conditions improved better than patients in the control group, he said.
Some pharmaceutical enterprises have already obtained drug approval from the State Food and Drug Administration for mass production in February, so the supply of favipiravir is guaranteed, he said, adding that researchers have already recommended the drug be included in the treatment plan as soon as possible.
The Third People's Hospital of Shenzhen in Guangdong province conducted a clinical trial on 80 patients, with 35 receiving the drug. The results showed that patients who took favipiravir tested negative within four days of treatment, whereas patients in the control group needed 11 days to test negative.
The lung conditions of 91.4 percent of the treated group improved as shown in chest imaging, compared with 62.2 percent of the control group, Zhang said.
In another experiment on 120 patients conducted by Zhongnan Hospital of Wuhan University in Hubei province, the treated group had a higher recovery rate at the end of the treatment; further, fever reduction and cough relief took less time for them, he added.
In terms of safety, Zhang said, the drug-developed in Japan and approved for marketing there in 2014-has shown no obvious adverse effects.
"In view of the safety, obvious efficacy and availability of the drug, researchers have officially recommended favipiravir to medical teams and suggested it be included in the treatment plan as soon as possible," he said.
Zhang said the research team will further promote the application of their research results in Wuhan and will promote the Chinese treatment plan in response to the current global pandemic situation.
- Chinese language week starts in New Zealand to promote Chinese language learning
- China’s new rice varieties up 40% yields
- Britain’s new PM prioritizes economy, energy, health service
- New Intl Land-Sea Trade Corridor records 20,000th sea-rail train
- China’s scientific research climbs to No. 1
- China’s new round of bulk procurement sees drug prices drop 48 pct
Popular Videos
Hot comments
- First apes at U.S. zoo receive COVID-19 vaccine made for animals, zoo official says
- China Life: Chinese women shine with She Power
- Foreign firms approved to offer VPN services in capital
- Homemade curling videos trending in China
- 86-year-old grandma in Hebei spends most her life on traditional cheongsam
- Winners of 2022 Inaugural WLA Prize announced
- Lantern Festival: A romantic celebration in China
- Two Chinese COVID-19 vaccine firms to supply vaccines to COVAX
- Media center for 20th CPC national congress to open on Oct. 12
- Six suspects arrested in HK for role in SE Asia job scam
Top Reviews
- Young artists recreate beauty of traditional Hanfu costume
- China releases photos of tallest tree
- English version of ‘Understanding Xi Jinping’s Educational Philosophy’ published
- China crowned in men’s team for 10th straight time at table tennis worlds
- China publishes Atlas of Wildlife in SW China
- Guangxi’s 10 Years: A Visit to China’s Qinzhou Port
- Congress delegate helped lift village out of poverty
- Expo highlights joint efforts in NEV development
- Racism stain of shame on ‘world democratic paradise’
- U.S. may face new COVID wave this upcoming winter: report